BIIB logo

Biogen Inc.

BIIB
Healthcare|Drug Manufacturers - General|US
$248.35
+4.42 (+1.81%)
DCF Value
$517.66
Graham Number
$82.35
Cash / Share
$8.82
Next Earnings Report
Feb 5, 2027
EPS est. $2.85 · Revenue est. $2.61B
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (36)

Dec 2026
Est. completion
P3Early Alzheimer's Disease
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
Jan 2027
Est. completion
P2ALS (Amyotrophic Lateral Sclerosis)
Tofersen in Non-SOD1 ALS
Feb 2027
Est. completion
Muscular Atrophy, Spinal
A Study of the Safety of Nusinersen (Spinraza®) and Its Effects on Motor Function in Koreans Living With SMA Treated During Their Usual Medical Care
Mar 2027
Est. completion
P2Parkinson Disease
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
Mar 2027
Est. completion
Postpartum Depression
A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone
Apr 2027
Est. completion
Spinal Muscular Atrophy (SMA)
Adult SMA Research and Clinical Hub
May 2027
Est. completion
P4Amyotrophic Lateral Sclerosis
A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)
May 2027
Est. completion
P3Immunoglobulin A Nephropathy (IgAN)
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Jun 2027
Est. completion
Spinal Muscular Atrophy Type 3
Gait and Bone Health in SMA
Sep 2027
Est. completion
Muscular Atrophy, Spinal
Pediatric Spinal Muscular Atrophy (SMA) China Registry
Sep 2027
Est. completion
Spinal Muscular Atrophy
Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA
Sep 2027
Est. completion
P3Spinal Muscular Atrophy
A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)
Sep 2027
Est. completion
P1Muscular Atrophy, Spinal
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
Oct 2027
Est. completion
P2Multiple Sclerosis
Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
Nov 2027
Est. completion
P3Friedreich Ataxia
A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia
Jan 2028
Est. completion
P2Graves' Disease
A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
Apr 2028
Est. completion
NASpinal Muscular Atrophy
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
Jun 2028
Est. completion
Muscular Atrophy, Spinal
Adult Spinal Muscular Atrophy (SMA) China Registry
Jun 2028
Est. completion
P1Healthy Volunteer
A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18 to 55 Years Old as Compared to a Placebo
Jun 2028
Est. completion
P3Spinal Muscular Atrophy
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam

Awaiting Results (4)

Trials past primary completion date but still active — data readout may be imminent.

Oct 2026
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
NCT05925049
Oct 2026
P2P3
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565
Sep 2026
An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
NCT06053749
Sep 2026
P3
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04961567

Recent Press Releases

SEC Filings (64)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 28, 202610-QQuarterly reportDocumentIndex
Oct 28, 20268-KMaterial eventDocumentIndex
Aug 6, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jul 29, 202610-QQuarterly reportDocumentIndex
Jul 29, 20268-KMaterial eventDocumentIndex
Jul 1, 20268-KMaterial eventDocumentIndex
Jun 10, 20268-KMaterial eventDocumentIndex
Jun 10, 20268-K/AMaterial eventDocumentIndex
Jun 5, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 14, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
May 14, 20268-KMaterial eventDocumentIndex
May 14, 2026SC TO-T/ATender offerDocumentIndex
May 12, 2026SC TO-T/ATender offerDocumentIndex
May 6, 2026SC TO-T/ATender offerDocumentIndex
May 6, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Apr 29, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 29, 202610-QQuarterly reportDocumentIndex
Apr 29, 20268-KMaterial eventDocumentIndex
Apr 28, 2026ARSAnnual report to holdersDocumentIndex
Apr 28, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 28, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 14, 2026SC TO-TTender offerDocumentIndex
Apr 7, 2026SC TO-CTender offerDocumentIndex
Apr 6, 2026SC 13DActivist / 5%+ stakeDocumentIndex
Apr 6, 20268-KMaterial eventDocumentIndex
Apr 3, 2026SC TO-CTender offerDocumentIndex
Mar 31, 2026SC TO-CTender offerDocumentIndex
Mar 31, 20268-KMaterial eventDocumentIndex
Mar 31, 2026SC TO-CTender offerDocumentIndex
Mar 26, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 11, 20268-KMaterial eventDocumentIndex
Feb 11, 20268-KMaterial eventDocumentIndex
Feb 6, 202610-KAnnual reportDocumentIndex
Feb 6, 20268-KMaterial eventDocumentIndex
Feb 5, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jan 14, 20268-KMaterial eventDocumentIndex
Nov 13, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 10, 2025SC 13GPassive 5%+ stakeDocumentIndex
Oct 30, 202510-QQuarterly reportDocumentIndex
Oct 30, 20258-KMaterial eventDocumentIndex